{rfName}
Do

Indexed in

License and use

Citations

33

Altmetrics

Analysis of institutional authors

Redondo ACorresponding Author

Share

Publications
>
Article

Dostarlimab for the treatment of advanced endometrial cancer

Publicated to:Expert Review of Clinical Pharmacology. 15 (1): 1-9 - 2022-01-01 15(1), DOI: 10.1080/17512433.2022.2044791

Authors: Redondo A, Gallego A, Mendiola M

Affiliations

Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. - Author
Department of Medical Oncology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. - Author
Faculty of Medicine, Universidad Autonoma de Madrid, Madrid, Spain. - Author
Hosp Univ La Paz, Dept Med Oncol, IdiPAZ, Paseo Castellana 261, Madrid 28046, Spain - Author
Inst Invest Hosp La Paz IdiPAZ, Mol Pathol & Therapeut Targets Grp, Madrid, Spain - Author
Inst Invest Hosp La Paz IdiPAZ, Translat Oncol Res Lab, Madrid, Spain - Author
Inst Salud Carlos III, Ctr Biomed Res Canc Network, CIBERONC, Madrid, Spain - Author
Molecular Pathology and Therapeutic Targets Group, Instituto de Investigación Hospital La Paz (IdiPAZ), Madrid, Spain. - Author
Translational Oncology Research Laboratory, Instituto de Investigación Hospital La Paz (IdiPAZ), Madrid, Spain. - Author
Univ Autonoma Madrid, Fac Med, Madrid, Spain - Author
See more

Abstract

Between 20% and 30% of the endometrial cancers (EC) are associated with a deficiency of a mismatch repair (MMRd) protein or high microsatellite instability (MSI-H), characteristics that render the tumor more sensitive to immune checkpoint inhibitors. There is no standard treatment for advanced EC after progression to a platinum-containing regimen.The phase I GARNET clinical trial assessed the safety, tolerability, and antitumor activity of anti-PD1 dostarlimab in patients with advanced solid tumors. The A1 cohort of this trial enrolled patients with MMRd or MSI-H recurrent or advanced EC who had previously received a platinum-containing regimen. The results of this cohort showed significant clinical activity, durable responses, and a favorable safety profile, without reducing quality of life. Based on these data, dostarlimab achieved accelerated approval.Although a randomized study has not yet been conducted, dostarlimab monotherapy should be the treatment of choice for patients with advanced MMRd EC in progression after a platinum-containing regimen. Selecting patients with EC for immune checkpoint inhibitors using the MMRd predictive biomarker could facilitate more efficient and sustainable health systems and avoid the use of more toxic combinations, leading to personalized medicine.

Keywords

dostarlimabimmune checkpoint inhibitorAdvanced endometrial cancerDostarlimabImmune checkpoint inhibitorPembrolizumab

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Expert Review of Clinical Pharmacology due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology, Toxicology and Pharmaceutics (Miscellaneous). Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 3.93. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 4.09 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 5.25 (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-30, the following number of citations:

  • WoS: 15
  • Scopus: 18

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-30:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 33.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 33 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 35.3.
  • The number of mentions on the social network X (formerly Twitter): 14 (Altmetric).
  • The number of mentions in news outlets: 3 (Altmetric).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (REDONDO SANCHEZ, ANDRES) .

the author responsible for correspondence tasks has been REDONDO SANCHEZ, ANDRES.